← Leaderboards
George E Woody
University Of Pennsylvania
$40,983,108
Attributed
$47,103,236
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,103,236 · 11
By mechanism
U10$25,753,724 · 1
UH3$8,178,365 · 1
R01$6,631,452 · 4
UG3$4,061,892 · 1
K05$1,262,140 · 1
R21$654,315 · 2
Top collaborators
- Kyle Matthew Kampman4 shared
Others in their field
Top investigators on “Buprenorphine”
- Sharon L. Walsh · University Of Kentucky$87,310,858
- Edward V Nunes · Columbia University Health Sciences$83,345,625
- T John Winhusen · University Of Cincinnati$34,249,969
- Walter Nmn Ling · University Of California Los Angeles$33,859,118
- Marco Pravetoni · Hennepin Healthcare Research Institute$33,709,846
- John P Rotrosen · New York University School Of Medicine$28,036,708
Research focus
BuprenorphineMethadoneOpioidAddictionPharmaceutical PreparationsProgramsNaloxonePersonsNaltrexoneTrainingHeroinDelawareRussiaPaperCounselingClinical Trials NetworkAgonistProtocols DocumentationRelapseMaintenanceResearch PersonnelPhiladelphiaFundingCountry
Grant awards (72)
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?$2,584,873
UH3 · FY2025 · DA
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?$2,708,839
UH3 · FY2024 · DA
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?$2,884,653
UH3 · FY2023 · DA
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?$4,061,892
UG3 · FY2019 · DA
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone$355,852
R01 · FY2016 · DA · contact PI
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone$377,881
R01 · FY2015 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$269,192
U10 · FY2015 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$940,977
U10 · FY2014 · DA · contact PI
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone$471,508
R01 · FY2014 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$245,881
U10 · FY2014 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$943,791
U10 · FY2013 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$786,447
U10 · FY2013 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$557,588
U10 · FY2013 · DA · contact PI
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone$452,648
R01 · FY2013 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$948,602
U10 · FY2012 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$775,738
U10 · FY2012 · DA · contact PI
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone$490,705
R01 · FY2012 · DA · contact PI
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone$382,782
R01 · FY2012 · DA · contact PI
PA-06-555 Senior Scientist Research and Mentorship Award (K05)$125,874
K05 · FY2012 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$946,934
U10 · FY2011 · DA · contact PI
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone$454,273
R01 · FY2011 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$309,821
U10 · FY2011 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$161,880
U10 · FY2011 · DA · contact PI
PA-06-555 Senior Scientist Research and Mentorship Award (K05)$125,874
K05 · FY2011 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$79,513
U10 · FY2011 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$73,600
U10 · FY2011 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$57,970
U10 · FY2011 · DA · contact PI
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone$18,194
R01 · FY2011 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$970,902
U10 · FY2010 · DA · contact PI
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone$459,608
R01 · FY2010 · DA · contact PI
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone$383,790
R01 · FY2010 · DA · contact PI
Suboxone and Methadone for HIV Risk Reduction in Subutex Injectors$145,581
R21 · FY2010 · DA · contact PI
PA-06-555 Senior Scientist Research and Mentorship Award (K05)$125,874
K05 · FY2010 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$1,250,000
U10 · FY2009 · DA · contact PI
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone$472,397
R01 · FY2009 · DA · contact PI
Suboxone and Methadone for HIV Risk Reduction in Subutex Injectors$201,438
R21 · FY2009 · DA · contact PI
PA-06-555 Senior Scientist Research and Mentorship Award (K05)$125,874
K05 · FY2009 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$100,388
U10 · FY2009 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$1,250,000
U10 · FY2008 · DA · contact PI
PA-06-555 Senior Scientist Research and Mentorship Award (K05)$125,874
K05 · FY2008 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$1,250,000
U10 · FY2007 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$330,020
U10 · FY2007 · DA · contact PI
Addiction Treatment in Russia: Oral and Depot Naltrexone$268,055
R01 · FY2007 · DA · contact PI
Methadone maintenance and HIV risk in Ukraine$142,319
R21 · FY2007 · DA · contact PI
Outcome of Treatment for Substance Use Disorders and HIV Risk Reduction$126,554
K05 · FY2007 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$1,250,000
U10 · FY2006 · DA · contact PI
Addiction Treatment in Russia:Oral and Depot Naltrexone$252,279
R01 · FY2006 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$173,721
U10 · FY2006 · DA · contact PI
Methadone maintenance and HIV risk in Ukraine$164,977
R21 · FY2006 · DA · contact PI
Treatment/Substance Use Disorders/HIV Risk Reduction$126,554
K05 · FY2006 · DA · contact PI
Delaware Valley Node of the Clinical Trials Network$1,200,870
U10 · FY2005 · DA
CLINICAL RESEARCH COOPERATIVE$300,001
U10 · FY2005 · DA
Treatment/Substance Use Disorders/HIV Risk Reduction$126,554
K05 · FY2005 · DA
CLINICAL RESEARCH COOPERATIVE$1,500,000
U10 · FY2004 · DA
Addiction Treatment in Russia:Oral and Depot Naltrexone$260,634
R01 · FY2004 · DA
CLINICAL RESEARCH COOPERATIVE$249,889
U10 · FY2004 · DA
Treatment/Substance Use Disorders/HIV Risk Reduction$126,554
K05 · FY2004 · DA
CLINICAL RESEARCH COOPERATIVE$1,500,000
U10 · FY2003 · DA
CLINICAL RESEARCH COOPERATIVE$779,999
U10 · FY2003 · DA
Addiction Treatment in Russia:Oral and Depot Naltrexone$285,603
R01 · FY2003 · DA
Treatment/Substance Use Disorders/HIV Risk Reduction$126,554
K05 · FY2003 · DA
CLINICAL RESEARCH COOPERATIVE$50,000
U10 · FY2003 · DA
CLINICAL RESEARCH COOPERATIVE$1,800,000
U10 · FY2002 · DA
PERSISTENT EFFECTS OF LT/LI DRUG RISK COUNSELING$419,706
R01 · FY2002 · DA
CLINICAL RESEARCH COOPERATIVE$400,000
U10 · FY2002 · DA
CLINICAL RESEARCH COOPERATIVE$2,100,000
U10 · FY2001 · DA
PERSISTENT EFFECTS OF LT/LI DRUG RISK COUNSELING$425,184
R01 · FY2001 · DA
TREATMENT STRATEGIES FOR METHODONE NONRESPONDERS$79,323
P60 · FY2001 · DA
TREATMENT STRATEGIES FOR METHODONE NONRESPONDERS$79,323
P60 · FY2001 · DA
CLINICAL RESEARCH COOPERATIVE$2,200,000
U10 · FY2000 · DA
TREATMENT STRATEGIES FOR METHODONE NONRESPONDERS$402,702
P60 · FY2000 · DA
PERSISTENT EFFECTS OF LT/LI DRUG RISK COUNSELING$400,353
R01 · FY2000 · DA